ARWR:NSD-Arrowhead Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 52.51

Change

-1.28 (-2.38)%

Market Cap

USD 5.66B

Volume

0.87M

Avg Analyst Target

USD 79.67 (+51.72%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Arrowhead Pharmaceuticals Inc (ARWR) Stock Analysis:
Based on the Arrowhead Pharmaceuticals Inc stock forecasts from 4 analysts, the average analyst target price for Arrowhead Pharmaceuticals Inc is USD 79.67 over the next 12 months. Arrowhead Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arrowhead Pharmaceuticals Inc is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Arrowhead Pharmaceuticals Inc’s stock price was USD 52.51. Arrowhead Pharmaceuticals Inc’s stock price has changed by -5.07% over the past week, -18.02% over the past month and -34.38% over the last year.

About

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver di ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-6.55 (-3.76%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

-3.73 (-0.60%)

USD66.47B 9.89 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-2.23 (-0.97%)

USD58.90B 27.78 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-5.13 (-3.17%)

USD39.21B 5.08 5.67
BGNE BeiGene Ltd

+14.52 (+6.13%)

USD24.26B N/A N/A
SGEN Seagen Inc

+0.51 (+0.38%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

-0.36 (-1.04%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

-0.66 (-1.65%)

USD17.17B 20.75 11.89

ETFs Containing ARWR

Symbol Name Weight Mer Price(Change) Market Cap
LABU Direxion Shares ETF Trust.. 0.00 % 1.02 %

-1.01 (-5.03%)

USD0.95B
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

-1.53 (-1.64%)

USD7.11B
XSU:CA iShares U.S. Small Cap In.. 0.00 % 0.36 %

-0.73 (-1.78%)

USD0.55B
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

-0.10 (-0.62%)

USD0.25B
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.08 %

-6.28 (-1.77%)

USD1.52B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.08 %

-5.92 (-1.88%)

USD7.85B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.30 %

+0.39 (+0.90%)

USD1.75B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.30 %

+0.71 (+1.39%)

USD1.77B
XRS2:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.30 %

+3.30 (+1.27%)

USD1.70B
DRUP:F Lyxor Index Fund - Lyxor .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.80% 36% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.80% 36% F 17% F
Trailing 12 Months  
Capital Gain -34.38% 69% D+ 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.38% 69% D+ 31% F
Trailing 5 Years  
Capital Gain 2,785.16% 98% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,785.16% 98% A+ 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 177.15% 92% A- 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 177.15% 92% A- 96% A
Risk Return Profile  
Volatility (Standard Deviation) 188.18% 13% F 7% F
Risk Adjusted Return 94.14% 99% A+ 93% A
Market Capitalization 5.66B 96% A 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 478.56 3% F 3% F
Price/Book Ratio 17.92 6% F 6% F
Price / Cash Flow Ratio 33.04 4% F 12% F
EV/EBITDA 739.74 1% F 2% F
Management Effectiveness  
Return on Equity -32.36% 76% C 35% F
Return on Invested Capital -34.24% 63% D 22% F
Return on Assets -15.11% 76% C 24% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.08 43% F 28% F
Short Percent 2.99% 62% D- 46% F
Beta 1.23 51% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.